<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><label>Table 2.</label><caption><title>Overview of antibiotic treatments showing the ten most used antibiotics in this patient cohort.</title><p>Intravenous (iv), oral (or), and intramuscular (im) route administration is given in percent of treatment days.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Antibiotic</th><th>Number of treated patients (total n=133)</th><th>Route</th></tr></thead><tbody><tr><td>Ceftriaxone</td><td>64</td><td>( 98% iv , 2% im )</td></tr><tr><td>Ciprofloxacin</td><td>34</td><td>( 67% iv , 33% or )</td></tr><tr><td>Metronidazole</td><td>20</td><td>( 50% iv , 50% or )</td></tr><tr><td>Cefuroxime</td><td>13</td><td>( 100% iv , 0% or )</td></tr><tr><td>Vancomycin</td><td>13</td><td>( 86% iv , 14% or )</td></tr><tr><td>Meropenem</td><td>10</td><td>( 100% iv , 0% or )</td></tr><tr><td>Amikacin</td><td>9</td><td>( 100% iv , 0% or )</td></tr><tr><td>Amoxicillin-clavulanic acid</td><td>9</td><td>( 57% iv , 43% or )</td></tr><tr><td>Piperacillin-tazobactam</td><td>7</td><td>( 100% iv , 0% or )</td></tr><tr><td>Imipenem</td><td>5</td><td>( 100% iv , 0% or )</td></tr></tbody></table></table-wrap>